Tagged with BI

Korea Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr Jisoo Pae, its co-founder and CEO, sat down with PharmaBoardroom to shed light on the company’s origins, its collaboration with Big Pharma, and the ease of gaining capital investment for a…

USA In a recent virtual town hall meeting hosted by BIO, two key leaders from the US FDA laid out how their organisation has adjusted in the wake of the COVID-19 crisis, at what stage of development diagnostics and therapeutics for the virus are, and the pandemic’s long-term effects – both…

Korea After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the US market and an Investigational New Drug (IND) approval from the FDA.   Dr Kyung Suk Kim, Corestem’s CEO, recently spoke to PharmaBoardroom to give an update on…

China Founded by a veteran industry team, Arctic Vision recently celebrated its first anniversary and touts itself as the first innovative ophthalmology-focused biotech in China, with the mission of bringing innovative therapies from abroad to patients in China.   According to CEO and cofounder Dr Eddy WU, a company like Arctic…

China Dr Eddy Wu, founder and CEO of new Chinese ophthalmology biotech Arctic Vision outlines the specific unmet ophthalmology needs in the Chinese market, the company’s burgeoning international partnerships, exciting portfolio, and Dr Wu’s own personal leadership journey.   From an R&D perspective … what is critical in ophthalmology is the…

China Yan Tan, CEO of Xbiome, the first AI-based microbiome drug development company in China, outlines the rationale behind the firm’s founding, what makes its technology platform unique, and the challenges of attaining funding for cutting-edge innovation.   Despite being a relatively new company, in 2019, we raised the most money…

China 2020 will certainly go down in history as a watershed year for the global community, as a new strain of coronavirus – later named SARS-CoV-19 – originating from the city of Wuhan in China circulated around the world in just months, wreaking havoc on economies and disrupting the lives of…

Taiwan Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their technology’s unique characteristics, how it differs from sequencing technologies in terms of cost and speed, and their strategy for the Asia-Pacific region and beyond.   Our solution is akin to capsule coffee. One machine can…

Roundup A roundup of the latest news from Chinese biotechs, including a bumper IPO for Legend Biotech, a USD two million tie-up between Roche and Innovent Biologics, and a new Alphamab-Sanofi collaboration on KN026 in HER2+ Breast Cancer.   Fresh off ASCO myeloma data, Legend Bio gets USD 424 million in…

Japan Japan’s pharma market is one of the world’s biggest, with a value of around USD 95 billion, according to figures from the country’s Ministry of Health, Labour and Welfare (MHLW). Japanese firms have a particularly strong standing in their home market, making up six of the country’s top ten pharma…

China Johnson & Johnson’s network of healthcare innovation incubators, JLABS, opened its doors in Shanghai in June 2019 and now stands as the largest such institution of 13 globally. JLABS @ Shanghai’s head, Dr Sharon Chan, recently sat down with PharmaBoardroom to explain the JLABS model, how it has had to…

Hong Kong Dr Albert Yu, chairman of the Hong Kong Biotechnology Organization (HKBIO) gives his expert insights into the crucial importance of diagnostics in countering the COVID-19 pandemic, how Hong Kong’s positioning within health technology is shifting, and why more and more biotech firms are choosing to IPO in Hong Kong.  …